BCBS denied my biologic for ulcerative colitis on the new plan even though i already failed step therapy on the old plan - specialty pharmacy is quoting $4,800/month out of pocket. how do i force the carrier to honor my prior step-therapy history instead of restarting the protocol?

switched insurance jan 1 from a UnitedHealthcare PPO (employer-sponsored) to a Blue Cross Blue Shield PPO (also employer-sponsored, but employer renegotiated carriers at renewal). same employer, same job, just a different carrier. i was on infliximab biosimilar (Inflectra) infusions every 8 weeks for moderate-to-severe ulcerative colitis. it has been working - i was in clinical and endoscopic remission per my last colonoscopy in november. cost on UHC was $42 copay per infusion after the specialty pharmacy negotiated price.

BCBS denied the prior authorization in february. denial language: "patient must demonstrate failure of, intolerance to, or contraindication to (1) oral or topical 5-aminosalicylate therapy for at least 8 weeks at maximum tolerated dose AND (2) oral corticosteroid therapy for at least 14 days OR budesonide MMX for at least 8 weeks before consideration of biologic therapy. records do not demonstrate completion of step therapy under this plan." then they kicked me to the specialty pharmacy at full cash price, which is $4,800/month for the biosimilar (the brand Remicade is $6,200/month, both insane).

the part that is making me lose my mind: i already DID the step therapy. it just happened under UHC, not BCBS. my GI documented:

- 14 months on mesalamine (Apriso then Lialda at maximum dose, 4.8g/day) starting summer 2022 with documented breakthrough flares on routine surveillance labs and 2 endoscopies showing active inflammation

- 2 separate prednisone tapers in 2023 (40mg starting dose, both times we hit relapse during taper around week 4-6)

- 1 budesonide MMX course in late 2023 (8 weeks, 9mg/day, no remission)

- transition to Inflectra in january 2024 after my GI documented "treatment-resistant moderate UC requiring biologic therapy per ACG guidelines"

all of this is in my medical record. my GI sent BCBS a 6-page letter of medical necessity with the full treatment timeline, copies of the colonoscopy reports, the medication history with start/stop dates and doses, and a citation to the ACG 2019 ulcerative colitis treatment guidelines (which explicitly support biologic therapy for patients who have failed 5-ASA and corticosteroid therapy regardless of which carrier covered which step). BCBS denied the first appeal on the same "step therapy not completed under this plan" language.

i am now in the second-level internal appeal and i am genuinely lost on how this plays out. specific questions for anyone who has been through a step-therapy reset / continuity-of-care fight on a biologic:

(1) is "step therapy reset on plan change" actually a legal position the carrier can hold? i have read conflicting things. some states have step therapy reform laws (NY, IL, CA, TX, OH, KY, NJ, CT, WA, MD, MO, and a growing list of others) that require carriers to accept documented prior step therapy from a previous plan as completion of the protocol. i am in ohio. ohio has SB 252 (passed 2018) that requires carriers to "consider" prior medication history and provides an exception process when prior step therapy has been documented. how do i invoke that statute in my appeal language? does the appeal have to specifically cite the statute or does the carrier have to consider it automatically?

(2) continuity-of-care argument. ACA and most state insurance laws require carriers to provide a continuity-of-care period (typically 90 days) for patients in active treatment with non-formulary or non-covered medications when switching plans. this should cover me at least through april for the infusion that was already scheduled in march. did BCBS just blow past their continuity-of-care obligation and is that a separate complaint i can file with the ohio DOI? if i file a DOI complaint does that pause the internal appeal process or run in parallel?

(3) medical exception / formulary exception process. separate from the step therapy appeal, BCBS has a "medical exception" process where the prescriber can request a non-formulary medication be covered at the formulary tier when there is a documented medical reason the formulary alternative is inappropriate. my GI submitted a medical exception form along with the appeal but BCBS combined the responses into a single denial. should i be pushing for separate adjudication of the medical exception under a different procedural track? how is that different from the step therapy appeal?

(4) external review timing. after the second-level internal appeal is denied (which i am expecting based on how the first level went), the external review process under ACA is the next step. for a specialty medication denial like this, what is the realistic timeline to external review? i have an infusion scheduled for march 18 and i cannot afford to skip a dose - flaring on a biologic that you have stopped and restarted is significantly worse than staying on the maintenance schedule. is there an expedited external review process for active-treatment situations and how do i invoke it?

(5) practical question - bridging the gap. the manufacturer (Pfizer for Inflectra) has a copay assistance program for commercially insured patients. would i qualify as "commercially insured" if BCBS is denying coverage, or does denial put me outside the commercial insurance population for purposes of the assistance program? has anyone navigated a manufacturer copay/patient assistance program during an active carrier appeal? does the manufacturer help bridge or do they only help once coverage is established?

(6) cost during the appeal window. if i need to do the march 18 infusion at cash price to avoid a flare, $4,800 is real money. is there any mechanism to recover that out-of-pocket cost retroactively if the appeal eventually succeeds? does the carrier owe reimbursement to the patient for amounts paid out of pocket during the appeal if the denial is overturned?

(7) attorney involvement. at what point in a specialty medication denial does it make sense to bring in an insurance attorney or a patient advocate? the financial exposure is meaningful (potentially $4,800-$6,200/month indefinitely if i lose), but i do not know if attorneys take cases like this on contingency or only on hourly. is there a healthcare-specific patient advocate role that handles these without an attorney?

my GI is fully on my side and is willing to keep documenting, citing guidelines, and writing appeal letters. the issue is i am running into a procedural wall - BCBS keeps responding with the same boilerplate "step therapy not completed under this plan" language regardless of what we send them. it feels like the appeals are being processed by people who are not reading the substantive medical documentation, they are just looking for the magic phrase "completed 5-ASA + corticosteroid step therapy under BCBS coverage" which obviously will never appear because i did the step therapy under a different carrier.

any concrete experience navigating this kind of denial would be enormously appreciated. thanks in advance.